Background {#Sec1}
==========

Randomised controlled trials (RCTs) are considered to be the 'gold standard' for assessing the effects of a treatment. However, these trials usually report results following a relatively brief exposure to the intervention under investigation. Longer-term follow-up of trial participants is important as persistent effects may be detected years later after treatment cessation or even enhanced benefits observed decades later -- a so-called 'legacy effect' \[[@CR1], [@CR2]\]. Furthermore, delayed hazards may only emerge several years after exposure to certain treatments. Therefore, PTFU may add significant scientific value to the evaluation of many healthcare interventions.

We define post-trial follow-up (PTFU) as extended follow-up which starts after the end of the scheduled period of the trial. Such follow-up, regardless of the primary in-trial outcome, provides important information including safety of the intervention, identification of delayed hazards and long-term beneficial effects.

Retention of participants in PTFU is important since high rates of attrition may introduce bias if reasons for withdrawal are related to the intervention \[[@CR3]\]. There are a variety of methods for PTFU, but little research has been done to evaluate which methods for PTFU leads to the best retention rates \[[@CR4]\]. Choice of follow-up method is often determined by the funding for the trial and the local availability of relevant data. Telephone calls, postal questionnaires and face-to face interviews are the more traditional approach to follow-up. Web-based approaches and use of routine health records and electronic registries are becoming more popular due to advancing technology and options for accessing the information inexpensively \[[@CR5], [@CR6]\].

This systematic review compares methods used in approaches to PTFU and aims to inform the design of PTFU for a wide range of randomised trials. The main objective was to evaluate the retention rates (or levels of attrition) of the participants followed up during PTFU and to compare this to the type of methodology used. A secondary objective was to compare the costs of post-trial methodology as funding is often limited.

Methods {#Sec2}
=======

The methods used in this systematic review have been described in detail previously \[[@CR7]\] and follow PRISMA guidelines Additional file [1](#MOESM1){ref-type="media"}.

Eligibility criteria {#Sec3}
====================

Briefly, all large (\> 1000 adult participants) RCTs which investigated a healthcare intervention (i.e. medicine, surgery or psychiatric in nature) and involved PTFU were included. Only studies published between 2006 and 2017 were included. Alternative medicines (e.g. acupuncture) or holistic interventions including physical therapy were excluded from the review. Large RCTs were only included due to the reduced risk of random error in the outcomes.

PTFU was defined as passive follow-up which had occurred either after the scheduled closure of the trial or after the primary results had been published.

Search strategy {#Sec4}
===============

The search was conducted in five bibliographic databases on 13 April 2017, including Embase (OvidSP) (1 March 1974 to 12 April 2017), Medline (OvidSP) (1946 to present), PubMed, Cochrane Central Register of Controlled Trials (Cochrane Library, Wiley) (issue 3 of 12, March 2017) and Cochrane Methods Register (CENTRAL) (Cochrane Library, Wiley) (issue 3 of 4, July 2017). Searches were then restricted to articles published in English since 2006. Full details of strategies are provided in Additional file [2](#MOESM2){ref-type="media"}. In addition, a database search for completed and ongoing studies was conducted at [ClinicalTrials.gov](http://clinicaltrials.gov) (<https://clinicaltrials.gov/>). Studies which were not yet published 'grey literature' were not included in the search strategy.

Data collection {#Sec5}
===============

Papers identified from the [ClinicalTrials.gov](http://clinicaltrials.gov) registry were imported into a MS Excel spreadsheet. Duplicates and studies which had less than 1000 participants were removed using a filter option. The selection of eligible papers followed a concordance strategy between two reviewers (RLB and DE) which ensured that concordance was \> 95% (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR7]\].Fig. 1PRISMA flow diagram detailing the process of study selection and data extraction. *HCI* healthcare intervention*, PTFU* post-trial follow-up*, RCT* randomised controlled trial

Medical interventions were defined as an intervention that was consumed orally, inhaled, or administered by intravenous or intramuscular injections including vaccines. A surgical intervention was defined as any intervention which was invasive (apart from those mentioned above and including blood transfusions). Potential studies were checked for eligibility by two reviewers who initially reviewed abstracts and then proceeded to full paper review in a step-wise process (Fig. [1](#Fig1){ref-type="fig"}).

In addition to those described in the protocol, some additional exclusions which were not originally listed were identified during the process of performing the systematic review in keeping with our definition of PTFU. This was required due to the heterogeneity of PTFUs. These include: (1) trials that were stopped before the scheduled closure of the trial; (2) cancer trials which had an open endpoint (e.g. survival as an endpoint with no clear scheduled plan of duration); (3) trials which continued with active intervention in the PTFU period with the primary outcome of safety and (4) trials eligible for inclusion but which did not contribute novel data as they only published additional subgroup or post-hoc analyses. A table of excluded trials is provided in Additional file [3](#MOESM3){ref-type="media"}.

Full papers deemed eligible for inclusion in the systematic review were extracted using a standardised Excel spreadsheet. Data was extracted by DE and RLB and concordance was checked. Primary outcome, healthcare intervention and attrition rates were tabulated for each study. Lead trialists were contacted via email to inform them of the systematic review and to clarify information where necessary. The papers included in the review were diverse with a range of interventions and different outcome measures. Due to the high level of clinical heterogeneity a meta-analysis was not possible.

Retention rates were calculated as the proportion of participants who were lost to follow-up compared to the overall total of those who started the PTFU period. Information about the cost of the PTFU was sought from study publications or via personal communication. Two attempts were made to contact the trialist via email and if there was no response or inadequate data, the trial was excluded from the cost analysis.

Assessment of risk of bias {#Sec6}
--------------------------

Risk of bias was assessed for each included RCT on their primary results using the Cochrane Risk of Bias tool. [Covdence.org](http://covdence.org) was used to assess the levels of bias (low risk, high risk or unclear risk) in each methodological domain (sequence generation, allocation of sequence concealment, blinding, incomplete outcome data, selective reporting bias and other bias) and decisions checked by one of the senior authors \[[@CR8]\]. The data recorded from [Covidence.org](http://covidence.org) was imported into Review Manager 5 (RevMan 5) for graphical representation \[[@CR9]\].

Results {#Sec7}
=======

From 57,352 papers identified, 65 studies with PTFU were included in the systematic review (Fig. [1](#Fig1){ref-type="fig"}). Fifty trials involved medical interventions and 15 involved surgical interventions. There were no eligible psychiatric trials which had (all \> 1000 participants). The duration of PTFU ranged from 1 to 20 years, with a median of 4.5 years of follow-up. The number of participants followed during the post-trial period ranged from 575 to 29 862.

Five methods of follow-up were identified: postal correspondence/questionnaire (19%); clinic appointments (35%); telephone interviews (26%); electronic data linkage (52%); and review of paper medical records (26%). In addition, in individual cases, specific follow-up was performed, e.g. endoscopy follow-up only \[[@CR10]\]. Electronic data linkage and medical records review were used exclusively together in 11% of papers; either were used in combination with other methods in 74%. Overall, 48% of trials used more than one method to follow-up participants in the post-trial period (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). On average, two methods were used for each PTFU follow-up. Where data linkage was used, it was not always feasible to follow up all participants \[[@CR11]\]. Some trials experienced difficulty accessing national electronic data in certain countries; for example, stricter regulations are apparent in Canada and for some North American participants (Medicare and Veteran Affairs) where a specific health ID number is required to access national data (Table [3](#Tab3){ref-type="table"}). Trials experienced difficulty in accessing routinely collected health records in 3% of included papers and PTFU was restricted to those countries with robust and accessible centrally held records and registries (e.g. Sweden and Scotland) \[[@CR12], [@CR13]\].Table 1Post-trial follow-up (PTFU) in eligible medical trials. Note retention of participants expressed as % lost to follow-up1st author, yearPrimary outcome for PTFURCT name (PTFU name)No. years PTFU^a^InterventionNo. randomised in-trialNo. at the start of PTFU% participants lost in PTFUType of PTFU for primary outcomePost/QClinicTelephoneData linkagePaper recordsOtherAlan, 2015MortalityProHOSP6CAP antibiotics13599256YYArbel, 2016MortalityBIP20Bezafibrate30903090--YArber, 2011Cancer, safetyPreSAP2Celecoxib1561104312YAvenell, 2012Mortality*RECORD*3Vitamin D, Calcium52924394--YBreitner, 2011Alzheimer's diseaseADAPT2Naproxen, Celecoxib252822331YBulbulia, 2011Mortality and morbidityHPS6Simvastatin20,536175190YYCauley, 2013Hip fractures, cancers, CVE and mortalityWHI5Calcium plus vitamin D36,282298621YCherry, 2014Mortality, cancerESPIRIT12Oestrogen10171017--YChew, 2013Progression of age-related macular degenerationAREDS5Antioxidants47573549--YYYChowdhury, 2014Diabetes mellitus, mortality, MACEANBP27ACE inhibitor, Thiazide60835678 (6083 linked to death registry)--YYCushman, 2012MACE, mortalityALLHAT13Amlodipine, lisinopril32,80417,722 (CVD), 27,755 (mortality)--YDienstag, 2011Progression of Hep CHALT-C4Peginterferon1050743--YEastell, 2015Bone mineral densityHORIZON-PFT3Zoledronic acid77651223--YYEbbing, 2010MortalityNORVIT, WENBIT4B vitamins684562610YEinstein, 2011Safety, immunogenicity--2HPV vaccine11066710Y--Erdmann, 2014Mortality, MI, stroke, MACE, (composite)PROactive3Pioglitazone523835999YYYYEzzedine, 2010Skin cancerSU.VI.MAX5Antioxidant vitamins12,741110542YYFlossman, 2007Colorectal cancerUK-TIA20Aspirin24492249--YYColorectal cancerBDAT20Aspirin51395139--YYFord, 2016Mortality and morbidityWOSCOPS20Pravastatin65955778--YGerstein, 2016MACE, mortality (composite)ACCORD (ACCORDIAN)3Intensive glucose control10,2518601--YYGluud, 2008MortalityCLARICOR3Clarithromycin437340291YGordon, 2012Efficacy and safetyREVEAL2Adalimumab12125757YGrau, 2009AdenomasAFPPS4Aspirin1121100714YYGrubb, 2013CancerREDUCE2Dutasteride82312751--YYHackshaw, 2011Event-free survivalOVER 50S TRIAL10Tamoxifen34493449--YHague, 2016Mortality, cancerLIPID10Pravastatin901477210YYYYYHayashino, 2009Diabetes mellitusPHI117Aspirin22,07122,071--YYHayward, 2015MACEVADT5Intensive glucose lowering vs standard therapy1791179122YYHolman, 2008Macrovascular outcomesUKPDS10Intensive glycaemic control3867327720YYYHornslien, 2015Stroke, MI, mortalitySCAST3Candesartan202912862YInvestigators, 2011Diabetes mellitusDREAM (DREAM ON)2Rosiglitazone, ramipril5269165318YJohnson, 2015Vaccine efficacySPS (LTPS)4Vaccine38,54368676YYJones, 2015Cancer, bone fracturesRECORD4Rosiglitazone444725461YYYKostis, 2011MortalitySHEP13Chlorthalidone4736----YKrane, 2016MACE, mortality (composite)4D8Atorvastatin12556373YLai, 2014Mortality, liver cancerATBC16*α*-tocopherol,β-carotene29,13329105--YLaterre, 2007MortalityADDRESS1Drotrecogin-α264026219YYYLeslie, 2011MortalityENIGMA4Nitrous oxide2050200217YYLeslie, 2015MACE, mortalityENIGMA-II1Nitrous oxide7112665112YYLewis, 2011MACECAIFOS5Calcium15101510--YLloyd, 2013MACE, cancers, mortalityPROSPER3Pravastatin58045188--YMenne, 2014Long-term micro, macrovascular benefitROADMAP (ROADMAP OFU)3Olmesartan medoxomil444921980YOgihara, 2011MACE, cancer, mortalityCASE-J (CASE-J Ex)3Candesartan, amlodipine472822322YRadford, 2014Bone mineral densityAuckland Calcium Study5Calcium1471140817YYRothwell, 2010Colorectal cancerThrombosis Prev Trial, Swedish Aspirin Low Dose Trial, Dutch TIA Aspirin Trial, UK-Tia Aspirin Trial, British Doctors Aspirin Trial12, 13, 17, 18, 20Aspirin16,48814033--YYYTenkanen, 2006MACE, cancer, mortalityHelsinki Heart Study10Gemfibrozil408140810YYWang, 2015Fracture incidenceNIT16Vitamins (14), minerals (12)331833181YYWeston, 2011Persistence of antibodies1063163Vaccine dip, pert, tetanus22841505--YWhiteley, 2014DisabilityIST-31Alteplase303523482YZoungas, 2014MortalityADVANCE (ADVANCE-ON)6Perindopril, indapamide11,1408494--YYwhere ^a^ is number of years (median/mean/max) published in the cited paper, years followed up to the nearest whole number, % participants lost to the nearest whole number,'--' no data available or not applicable where mortality records were sought, *CVD* cardiovascular disease, *MACE* major adverse cardiovascular events ± revascularisation, *MI* myocardial infarction. Where 0 participants have been lost to follow-up this has been confirmed either in the cited paper or directly with the corresponding trialistTable 2Post-trial follow-up (PTFU) in eligible surgical trials. Note, retention of participants is expressed as % lost to follow-up1st author, yearPrimary outcome for PTFURCT name (PTFU name)No. years PTFU ^a^InterventionNo. participants randomised in trialNo. participants at the start of PTFU% participants lost in PTFUMethod of PTFU for primary outcomePost/QClinicTelephoneData linkagePaper recordsCarson, 2015MortalityFOCUS3Blood transfusion20162002--YCho 2017Mortality, MI, stroke, revascularisationRISPO4RIPC, RIPostC1328128015YYYGada, 2013Safety, efficacy, mortalitySPIRIT III5EES, PES1002----YGallagher, 2014MortalityRENAL (POST-RENAL)4Renal replacement therapy15081464--YHalliday, 2010Mortality, strokeACST-14CEA or deferement31203120--YHenderson, 2015MortalityRITA-35PCI181018100YHirsch, 2007Mortality, MACEICTUS4PCI120011243YYYHochman, 2011Mortality, MACEOAT3PCI22011504--YYYInvestigators, 2007MortalityBARI5PTCA182918294YYYMilojevic, 2016MortalitySYNTAX5PCI1800847--YYYNaunheim, 2006MortalityNETT2Lung-volume surgery121870%--YYPatel, 2016MortalityEVAR-113EVAR125212522YYYPowell, 2007MortalityUKSAT12Early AAA repair109010900YSedlis, 2015MortalityCOURAGE6PCI22871211--YWallentein, 2016Mortality, MI (composite)FRISC-II15PCI245724211YYwhere ^a^ is number of years (median/mean/max) published in the cited paper, years followed up to the nearest whole number, *PCI* percutaneous coronary intervention ± revascularisation, *PTCA* percutaneous transluminal coronary balloon angioplasty, *EES* everolimus-eluting stents, *PES* paclitaxel-eluting stents, *EVAR* endovascular aneurysm repair, *CEA* carotid endarterectomy, *AAA* abdominal aortic aneurysm, *RIPC* remote ischaemic preconditioning, *RIPostC* RIPC with postconditioning, *MI* myocardial infarction, *MACE* major adverse cardiovascular events ± revascularisation, *Postal/Q* postal communication or questionnaire, years followed up to the nearest whole number, % participants lost to the nearest whole number, 70% provided by trialist. Where 0 participants have been lost to follow-up this has been confirmed either in the cited paper or directly with the corresponding trialistTable 3Registries used for data linkage during post-trial follow-up (PTFU)CountryRegistryDatasetWebsiteUSAUnited States Renal Data System (USRDS)Renal[www.usrds.org](http://www.usrds.org/)Centres for Medicare and Medicaid Services (CMS (\[formerly HCFA))^a^Non-fatal events[www.cms.gov](http://www.cms.gov/)National Death Index Plus DatabaseCause- specific mortality<https://www.cdc.gov/nchs/ndi/>National Death Index and Social Security AdministrationAll-cause mortality<https://www.cdc.gov/nchs/nvss/deaths.htm>The Central Veterans Affairs Medical Information filesAll-cause morbidity<https://www.va.gov/directory/guide/facility.asp?ID=5380>The Veterans Affairs Death FilesAll-cause mortality<https://www.archives.gov/research/alic/reference/vital-records.html>CanadaStatistics Canada Mortality DatabaseAll-cause mortality<http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3233>EnglandNHS Digital (formerly HSCIC and Office of National Statistics)Non-fatal events, all-cause mortality<https://digital.nhs.uk/>ScotlandInformation and Statistical Division of the National Health Service for Scotland (Scottish Morbidity Record, General Register Office Death Record)All-cause morbidity, mortality<http://www.isdscotland.org/>IsraelMinistry of Health from the Israeli Population RegistryAll-cause mortality<https://www.health.gov.il/English/Pages/HomePage.aspx>Israel National Cancer RegistryCancer<https://www.health.gov.il/English/MinistryUnits/HealthDivision/Icdc/Icr/Pages/default.aspx>HollandDutch Central Bureau of StatisticsAll-cause mortality<http://www.iamexpat.nl/expat-page/official-issues/organisations/statistics-netherlands-cbs>NorwayCardiovascular Disease in Norway (CVDNOR) project (for data \< 2008)^b^Cause-specific morbidity<https://cvdnor.b.uib.no/>FinlandCause-of-Death Register (Statistics Finland)All-cause mortality<http://tilastokeskus.fi/til/ksyyt/index_en.html>Population Register Centre ^c^Demographics<http://vrk.fi/en/frontpage>Finnish Cancer RegistryCancer<http://www.cancer.fi/syoparekisteri/en/>AustraliaWestern Australia Data Linkage System (WADLS)Non-fatal events, all-cause mortality<http://www.datalinkage-wa.org.au/>^a^ Data only available for those with a valid Medicare or Social Security number (65% of all participants in the ALLHAT long-term follow-up), ^b^Registry linkage in Norway only available from 2008, ^c^ A personal identification number issued to each Finnish resident accesses demographic and medical records

Retention rates {#Sec8}
===============

Unfortunately, retention rates were often poorly reported in the PTFU, limiting the ability to assess the impact of methods used in relation to the proportion lost to follow-up.

All surgical trials investigated mortality as the primary outcome and, where data was available, the proportion of participants lost to follow-up in surgical trials ranged from 0.4 to 15.5%. However, data was not available for 53% of surgical trials. In medical trials, the primary outcome investigated varied more widely, although mortality as an endpoint was common and the proportion of participants lost to follow-up ranged from 0 to 22%. Data on loss to follow-up was not available in 44% of trials. Where mortality was the primary outcome, the number of participants lost to follow-up was not available in 32% of trials due to the use of mortality records where only notifications of deaths were fed back to the trialists.

Cost {#Sec9}
====

Financial information was available for one third of the included trials. Consequently, it was not possible to provide a direct comparison between cost of PTFU and the different methodologies used due to the small sample size. The cost of PTFU ranged from £6000 to £14,600,000 (Table [4](#Tab4){ref-type="table"}). Cost of PTFU per participant per year showed that IST-3 was the most economical costing £0.21 per participant per year using data linkage/medical records, closely followed by 'Over 50s' (£0.41) and RECORD trials (£0.46) which also used data linkage. LTPS was the most expensive PTFU per participant per year (US\$531.53) using clinical appointments and telephone follow-up. ROADMAP which also followed up participants by clinic appointment only had a cost of €413.60 per participant per year.Table 4Comparing post-trial follow-up (PTFU) costs (where disclosed), by different follow-up methodologiesType of follow-up, name of RCT or PTFUNumber of participants in PTFUDuration of PTFU\*Incentive for participant follow-upCost of PTFU/grant receivedCost per participant per yearClinical appointment only ROADMAP21983.3Travel reimbursement €20 per visit€3,000,000€413.60Clinical appointment + telephone LTPS68674--US\$14,600,000US\$531.53Data linkage/medical records only RECORD43943No£6,000£0.46 FOCUS20023NoUS\$75,000US\$12.49 NORWIT, WENBIT62614Letters sent to offer withdrawal from PTFU (registry follow-up)NOK 16,000NOK 0.64 RENAL14644NoUndisclosed -- original recruiting sites paid for finding and contacting participants CLARICOR40293--£1,100,000£91.01 'Over 50s'344910no£14,000£0.41 RITA-318105--£359,577£39.73 SCAST12863no£7,000€1.81 CAIFOS15104.5noAUD 848,206AUD 124.83 IST-323481no£500£0.21Telephone + data linkage/medical records ProHOSP9256noNegligible. Students conducted telephone follow-up as part of their training-- OAT15043noUS\$100 administrative start-up, US\$50 per call for each follow-up, US\$30 per subject for re-consent payment, US\$300 per event completing reporting-- ENIGMA20023.5noAUD 53,807AUD 7.68 ENIGMA-II66511noAUD 60,000AUD 9.02Postal correspondence + data linkage/medical records HPS17,5196--£250,000£2.38 ANBP269836.9noAUD 18,000AUD 0.37 ACST-131204--£120,000£9.62 VADT17915US\$10 per survey gift cardUS\$10,00,000US\$111.67Postal correspondence +telephone + medical records ADDRESS26211noUS\$13,10,500US\$500where ^a^; median/max/range published in the cited paper, *RCT* randomised controlled trial, *PTFU* post-trial follow-up, *NOK* Norwegian Krone, *AUD* Australian dollar; '*-'* no data available/ declined by corresponding trialist, '\~' ,estimate; + RCT number as PTFU data not available. Results to 2 decimal places for cost per participant

Cochrane Risk of Bias {#Sec10}
=====================

We hypothesised that those RCTs which had poor methodology or 'high risk of bias' might subsequently have a PTFU which was poorly organised and, therefore, have low retention rates (or a high proportion lost to PTFU). Of the 65 papers included in the systematic review, seven were excluded from the risk of bias assessment: these were PTFUs which followed-up an amalgamation of data from more than one trial or were part of a systematic review and, therefore, not suitable to be included in the analysis (the risks of bias from individual component trials could not be combined).

Of the 58 trials considered, the risk of bias could not be fully assessed in 11 trials due to lack of information in at least one domain. Low (or unclear) risk of bias in all domains was found in 43 (74%) of those assessed. Only seven trials (12%) had at least one domain which was high risk of bias, of which one had two domains at high risk (Fig. [2](#Fig2){ref-type="fig"}). Details of the individual risk of bias domains for each included study are provided in Additional file [4](#MOESM4){ref-type="media"}.Fig. 2Cochrane Risk of Bias graph. Review authors' judgements about each risk of bias item presented as percentages across all included studies

Given the small number of trials found to have a high risk of bias in at least one domain and the highly variable retention rates observed during PTFU (Table [5](#Tab5){ref-type="table"}), it is not possible to draw any clear conclusions with respect to possible associations between risk of bias and its potential impact on the proportion of participants that were lost to follow-up in the post-trial period.Table 5Comparison of randomised controlled trials (RCTs) which had high risk of bias compared to the proportion lost to follow-up during post-trial follow-up (PTFU). A summary of those RCTs with no risk of bias are also detailedHigh-risk domainNumber of studies with high-risk domainProportion of participants lost to follow-up during PTFU (%)Blinding participants and personnel33.96--6.16Incomplete outcome data2--Other sources of bias31.21--11.79Selective outcome reporting11.2Low risk of bias in all domains43 (no high/unclear risk of bias)0--19.90

Discussion {#Sec11}
==========

This systematic review identified that PTFU methods varied and many trials used overlapping approaches which were more costly than needed. Data was limited on retention rates and so it was difficult to draw any firm conclusions on which method was best for PTFU.

Our main findings suggest that most PTFU published in the last 11 years does not appear to be designed in a cost-effective manner. Cost of PTFU was shown to vary widely and not many trials used incentives to retain participants. Despite only a third of trialists providing complete financial information for PTFU, follow-up by clinical appointment appeared to be the most expensive method, as might be expected given the resource implications. Postal or telephone correspondence in addition to data linkage did not appear to increase the cost per participant per year considerably. However, the effect of inflation over the 11 years included in this systematic review, makes quantitative comparison of cost differences difficult. Given the limited data available we have not attempted to adjust for inflation.

Data linkage or access to medical records is likely to be the most cost-effective method of following participants due to minimal staff required. However, a number of trialists highlighted the limitations of this approach, noting it to be time-consuming and frustrating with increasing regulatory costs and country-specific restrictions. In the UK, the process of accessing data electronically has become more stringent and costly, and markedly different to the processes which were encountered 10 years ago. There is also an issue of the data lagging behind by up to 2 years in some countries, which can impact on the completeness of results for a trial. Despite this, data linkages to national registries and electronic health records have been shown to be a valid and reliable method of PTFU \[[@CR12]--[@CR15]\].

When designing this systematic review, we anticipated that papers published in the early half of the last 11 years would choose more traditional methods of PTFU, e.g. clinic- and telephone-based approaches, and more recent trials may increasingly use data linkage where available. However, this has not been the case. The majority of trials have used a variety of different methods to capture data for the same primary outcome. We were, therefore, unable to compare retention rates by each type of method used. In addition, sparsity of complete data in the review (typically poor reporting of the final number of participants at the end of the follow-up period) limited the ability to assess retention rates achieved with different PTFU methods.

We found limited evidence of high risk of bias in the methodology of the in-trial periods. A likely explanation for this is that the majority of the trials included in this review were well-designed, large RCTs in which results were published in high-impact journals. Furthermore, trials which employ poor methodology or have had negative results are more likely not to engage in PTFU due to lack of funding or interest.

Due to new guidelines (Consolidated Standards of Reporting Trials (CONSORT)) recommending increasing transparency in the reporting of RCTs, a more complete capture of data would be likely for any future study \[[@CR16]\]. Research into appropriate methods in PTFU can only occur if there is transparency of the logistical and financial implications including number of participants lost to follow-up.

Conclusions {#Sec12}
===========

Post-trial follow-up of large RCTs can contribute significantly to the scientific value of a trial by determining the longer-term magnitude of the effects of an intervention. PTFU is valuable to ensure that there are no long-term hazards or beneficial effects which have been missed due to the common short in-trial periods for following up participants. However, it is not widely used as shown by the small number of eligible trials which had PTFU from the original search strategy.

Data linkage and the use of registries appear to be the most plausible and economical approach to PTFU. These methods also have the advantage of providing data for a wide range of endpoints. Improvement of electronic reporting and informatics could lead to better reporting and allow this type of method to be widely used.
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